1. Introduction {#sec1}
===============

Migraine is a common disabling primary headache disorder \[[@B1]\]. Epidemiological studies revealed that the global age-standardized prevalence of migraine was 14.4% (13.8--15.0%) in 2016, and this figure was 18.9% (18.1--19.7) for women and 9.8% (9.4--10.2) for men; in addition, the prevalence by ages increased significantly until reaching a peak between 35 and 39 years and decreased smoothly after 40 years, and for China, the prevalence of migraine was 9.3% (8.5--10.1%) in 2009 \[[@B2], [@B3]\]. Migraine has two major subtypes, "migraine without aura" and "migraine with aura," and the mechanism of migraine is related to vascular, pain pathway, central system \[[@B1]\]. Acute treatments for migraine usually include using aspirin or triptans (a highly selective serotonin 5-HT~1B~ and 5-HT~1D~ receptor agonists), and other drugs, whereas preventive treatment adopts drugs, cognitive behavioral therapy, and other therapeutic methods \[[@B4], [@B5]\].

Acupuncture is a kind of physical therapy, which is an essential component of "Traditional Chinese Medicine" (TCM) \[[@B6]\]. TCM theory believes that a kind of critical energy called Qi maintains the regular operation of the human body and this energy flows in a network of channels called meridians. The theory of TCM also believes the human body will suffer from illness or disease once this flow is abnormal, which can be recovered by inserting the needle in some specified points on the channels of meridians of the human body like acupuncture. Acupuncture is often used to treat headache including migraine \[[@B7]\], and its therapeutic mechanism may be related to its regulation of nitric oxide synthase and 5-hydroxytryptamine (5-HT) gene~1F~ expression to improve cerebral vasodilation and contraction \[[@B8]\].

Systematic reviews can provide a robust review of the effectiveness of clinical interventions \[[@B9]\]; according to the literature search, clinical researchers have completed a number of systematic reviews of acupuncture treating migraine. To summarize the evidence of acupuncture for migraine \[[@B10]\] and show the effect of acupuncture for acute and preventive treatment of migraine, the researchers carried out an overview of systematic reviews/meta-analyses (SR/MA) of randomized controlled trials (RCTs) on acupuncture for migraine.

2. Material and Methods {#sec2}
=======================

2.1. Studies Searches {#sec2.1}
---------------------

We searched PubMed, Excerpta Medica database (Embase), the Cochrane Library, China Knowledge Resource Integrated Database, VIP Chinese Journal Full Text Database, WANFANG Data, and China Biology Medicine disc from their establishment to May 27, 2018, with the following search terms: "migraine^*∗*^," "status migrainosus," "sick headache," "acupuncture," "needle," "needling," "thorns," "dry-needling," "body-acupuncture," "stitch," "tapping," "electroacupuncture," "electro-acupuncture," "prick," "pricking," "bloodletting," "puncturing collateral," "bleeding therapy," "Acusector," "quick puncture," "blood-letting," "systematic review," "SR," "systematic evaluation," "systematic assessment," "meta-analysis^*∗*^," and "Cochrane review."

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The inclusion criteria were as follows: ① Type of studies: SR/MAs of randomized controlled trials, ② Type of participants: migraine diagnosed by any internationally recognized or accepted clinical guideline or consensus like *The International Classification of Headache Disorders*, *3rd edition (beta version)* \[[@B1]\], ③ Type of interventions: the experimental groups were treated with acupuncture, which contained acupuncture with electrical stimulation and other acupuncture techniques with needles inserted into the skin, ④ Type of control: the control groups were treated with other blank controls, placebo, drug treatments, or other TCM treatments ⑤ Type of Outcomes: the primary outcomes were as follows: (a) pain intensity rated by measure tools: visual analogue scales (VAS), numerical rating scales (NRS) score, and verbal rating scale (VRS) score; (b) usage of (rescue) analgesics (any continuous or rank measures available), which was recommended by *Initiative on Methods*, *Measurement*, *and Pain Assessment in Clinical Trials* \[[@B11]\]; and (c) severe events; secondary outcome was frequency of migraine attacks (per 4 weeks or per month), headache frequency or times (per 4 weeks or per month), the number of migraine days (per 4 weeks or per month), the number of headache days (per 4 weeks or per month), and effective rate (curing rate or improving rate evaluated by researchers or subjects of studies included), which is lack of international recognition but commonly used in some Chinese literature. With the following situations, the studies were excluded: ① non-SR/MA, ② non-Chinese and English studies, and ③ no full-text studies were available.

2.3. Data Extraction {#sec2.3}
--------------------

All searched studies were imported into Endnote X8.0 for document management. Two coauthors (YH, HC) screened the titles and abstracts of all studies according to the inclusion and exclusion criteria, and then full texts of possible relevant studies were screened. Any disagreement was resolved by consulting another coauthor (XL).

EpiData 3.1 was used to extract the following items data by three coauthors (YL, HC, and XL): ① Basic information of included SR/MAs: the number of studies, interventions, and main conclusions; ② Methodology and evidence certainty of included SR/MAs: methodological information of SR/MA that recorded in *AMSTAR-*2 (a measurement tool to assess systematic reviews) \[[@B12]\], certainty of evidences reviewed by *GRADE* (Grading of Recommendations, Assessment, Development, and Evaluations) \[[@B13]\]; ③ Effect of intervention: outcomes of SR/MAs.

2.4. Assessment of Methodology of Included Reviews {#sec2.4}
--------------------------------------------------

AMSTART-2 was used to assess the methodological quality of included SR/MAs: When no or only 1 nonkey items did not conform, inferring rating overall confidence in the results of the SR/MA as *high*; when more than 1 nonkey item did not conform, inferring rating overall confidence in the results of the SR/MA as *moderate*; when 1 key item did not conform with nonkey items conforming or not conforming, inferring rating overall confidence in the results of the SR/MA as *low*; and when more than 1 key items did not conform with nonkey items conforming or not conforming, inferring rating overall confidence in the results of the SR/MA as *critically low*.

2.5. Statistical Analysis {#sec2.5}
-------------------------

We use frequency to show data (types of included studies\' therapies, types of outcome indexes, AMSTAR-2 compliance items, outcome indexes of meta-analysis, meta-analysis results, and so on). Microsoft Excel 365 was used for data visualization: Reformat data extracted from the underlying systematic reviews in tables.

According to SR/MAs, the results of quantitative synthesis were reported in the form of standard mean deviation (SMD), weighted mean deviation (WMD), odds ratio (OR), or relative risk (RR). And the results were also reported with 95% confidence intervals (CI).

3. Results {#sec3}
==========

3.1. Study Selection Process {#sec3.1}
----------------------------

A total of 428 studies were initially searched. 52 studies were selected after reading the title and abstract, and 15 SR/MAs were included in the overview after viewing full texts \[[@B7], [@B14]--[@B27]\], which included 2 Cochrane systematic reviews (9.5%) \[[@B7], [@B14]\] and 19 non-Cochrane system reviews (90.4%). The study selection process is shown in [Figure 1](#fig1){ref-type="fig"}.

3.2. Study Characteristics {#sec3.2}
--------------------------

The basic information of the included studies is presented in [Table 1](#tab1){ref-type="table"}. For the 15 SR/MAs, 13 studies included migraine patients \[[@B14]--[@B22], [@B24]--[@B27]\], 1 included episodic migraine patients (participants had been diagnosed with episodic migraine) \[[@B7]\] and one study included menstrual migraine patients (participants had been diagnosed by *the International Classification of Headache Disorders s-1/2/3* or criteria of menstrual migraine in *Criteria for the Diagnosis and Therapeutic Effect of Diseases and Symptoms in Traditional Chinese Medicine* \[[@B30]\] published by the State Administration of Traditional Medicine of China) \[[@B23]\]. For the timing of intervention, 11 studies did not define acute or preventive treatment, whereas 1 study was for acute treatment \[[@B25]\] and 3 studies were for preventive treatment \[[@B7], [@B24], [@B26]\].

3.3. Certainty of Evidences of Systematic Reviews Included {#sec3.3}
----------------------------------------------------------

In the certainty of the evidence, only 4 studies were reviewed by *GRADE* \[[@B7], [@B16], [@B23], [@B24]\], the certainty of the evidence of these studies was like [Table 2](#tab2){ref-type="table"}.

3.4. Methodological Quality {#sec3.4}
---------------------------

In the aspect of methodological quality, no studies were all conformed, and one was *low* rating overall confidence in the results \[[@B7]\], and fourteen were *critically low* rating overall confidence in the results \[[@B14]--[@B27]\], like [Table 3](#tab3){ref-type="table"}.

3.5. Meta-Analyses Outcomes of Intervention {#sec3.5}
-------------------------------------------

### 3.5.1. Outcomes of Pain Improvement {#sec3.5.1}

For the *VAS score*, 2 SRs reported it as meta-analyses (MAs) outcomes like [Table 4](#tab4){ref-type="table"} \[[@B18], [@B25]\]. For the headache situation, 5 SRs reported it as MAs outcomes like [Table 5](#tab5){ref-type="table"} \[[@B7], [@B14], [@B20], [@B24], [@B26]\].

### 3.5.2. Outcomes of Efficacy {#sec3.5.2}

For efficacy, 12 SRs reported it as MAs outcome indexes like [Table 6](#tab6){ref-type="table"} \[[@B7], [@B14]--[@B17], [@B19], [@B20], [@B22]--[@B24], [@B26], [@B27]\].

### 3.5.3. Outcomes of Safety {#sec3.5.3}

For adverse events, 9 SR/MAs reported adverse events \[[@B7], [@B14]--[@B16], [@B21], [@B23], [@B24], [@B26], [@B27]\], but only 4 reported it as MAs outcome indexes like [Table 7](#tab7){ref-type="table"} \[[@B7], [@B14], [@B16], [@B24]\].

4. Conclusions of SR/MAs Included {#sec4}
=================================

In terms of conclusion, the results of all 15 (100%) SR/MAs were positive. For treatment, 6 SR/MAs reported acupuncture had superiority relative to drugs \[[@B7], [@B16], [@B17], [@B19], [@B26], [@B27]\]; 4 SR/MAs reported acupuncture had superiority relative to sham acupuncture, drugs \[[@B14], [@B18], [@B22], [@B24]\]; 3 SR/MAs reported acupuncture had superiority relative to sham acupuncture \[[@B20], [@B21], [@B25]\]; 1 SR/MA reported acupuncture had superiority relative to drugs, other TCM treatments \[[@B16]\]. 1 SR/MA reported that acupuncture had superiority in treating migraine, but did not mention the control group in the conclusions \[[@B23]\].

5. Discussions {#sec5}
==============

5.1. Summary of Main Findings {#sec5.1}
-----------------------------

This overview included a considerable number of SR/MAs, illustrating that acupuncture has the advantage in pain improvement of VAS score, headache days/frequency, analgesic use and efficacy of response rate, and effective rate according to the present evidence. However, most SR/MAs included did not conclude firmly because of the small size or low methodological quality of the included trials and subjectively evaluated outcome of included trials, and some SR/MAs also stated that high-quality acupuncture for migraine RCT was still needed to confirm the main findings further. Based on previous evidence we reviewed, we supposed acupuncture might be a kind of available treatment for migraine in preventive or acute treatment, but in consideration of low methodological quality of present SR/MAs or RCTs of acupuncture for migraine, we need more high-quality evidence to demonstrate the effect of acupuncture for migraine.

5.2. Designs of Present SR/MAs {#sec5.2}
------------------------------

There was some advice for later researchers to carry out high-quality SR/MAs or RCTs of acupuncture for migraine, which was summarized according to designs of present SR/MAs.

5.3. Participants {#sec5.3}
-----------------

Most studies included did not mention whether the patients they included were with acute attacks of migraines or not, which reduce the significance of most included SR/MAs in revealing the suitable timings of applying acupuncture for migraines. Therefore, later researchers can get more meaningful results with a more clear statement of patients\' conditions like whether they are with aura or attacks.

5.4. Control Group {#sec5.4}
------------------

The control interventions included in SR/MAs were blank control, sham acupuncture, and drug treatment. In addition, one of the heterogeneity sources may be regarding different types of drug treatment as 1 kind of subgroup. As a result, later researchers should provide a clear comparison of intervention vs. control in their studies, which can not only improve the robustness of results but also offer suggestions of combined therapy including acupuncture in clinical practice.

5.5. Outcome {#sec5.5}
------------

The most common outcomes were about an effective rate. And results of SR/MAs in most outcomes were contradictory, which means we inferred that the efficacy is evaluated by both patient\'s own pain feeling and the estimate of different doctors; therefore, a certain degree of subjectivity in evaluation might appear, hence the difference in medical sets, communicating skills of doctors or other factors in each SR/MA, which can lead to bias in the conclusions of SR/MAs. We consider that SR/MAs and RCTs of acupuncture for migraine have problems with outcome indexes, for instance, outcomes were difficult to be evaluated stably and were also not international recognized like other clinical studies of other TCM treatments \[[@B31]\]. So, later researchers can also increase the reliability of their studies by regarding international recognized outcomes as outcomes in their studies.

5.6. Methodological Quality and Evidence Certainty of Systematic Reviews Included {#sec5.6}
---------------------------------------------------------------------------------

Researchers of included SR/MAs generally concluded that the reliability of their own SR/MAs evidence was low, more high-quality, large sample of acupuncture treating migraine RCT trials were needed, and the low quality of acupuncture treating migraine may affect the reliability of the evidence of SR/MAs in acupuncture for migraine. In addition, this study suggests that some researchers of SR/MAs did not synthesize data of different follow-up time and whether were grouped with acute attacks or not, respectively, which may also affect the heterogeneity of results provided by SR/MAs and reduce the certainty of their studies. And there were only 4 studies using *GRADE* to review the certainty of the evidence, whereas most meta-analysis outcomes were low or very low certainty. As assessment of *AMSTAR-2*, SR/MAs in acupuncture treating migraine need to be improved in methodology and reporting quality as these points below: lack of research protocol statement and registration may affect the transparency of the research results, lack of showing and explaining the reason of excluding studies may leave some information missing, lack of revealing funding sources of included studies may make researchers or readers ignore potential benefits and conflicts, and lack of statement of self-interest relationship may make readers ignore factors affecting objectivity and reliability of SR/MAs.

The core reason of low methodological quality of SR/MAs may be that a large portion of researchers of SR/MAs in acupuncture for migraine may not receive standard evidence-based medical education; therefore, we should strengthen and improve the work of evidence-based medicine education in higher education and continuing education of TCM, especially with the selection of suitable outcomes.

5.7. Strength and Limitations {#sec5.7}
-----------------------------

The strengths of this study were as follows: ① both English and Chinese studies were included to promise included studies widely and ② each MAs outcome was showed in structured tables which can help readers realize or review interesting outcomes easily. The limitations of this study were as follows: ① SR/MAs included were all low quality, which may reduce the confidence of the results, and ② the conflicts of interest of SR/MAs included were not analyzed, which may induce to miss some information.

6. Conclusions {#sec6}
==============

From this study, we found that acupuncture has the advantage for acute and preventive treatment of migraine in pain improvement and safety, but the quality of SR/MAs of acupuncture for migraine still needs to be improved.
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###### 

Basic information of included studies.

  Study ID                   Participant                   Acute or preventive treatment   Intervention                                                    Control                                                             Outcome measures                                                                        Design   Trials (participants)   Risk of bias assessment tool
  -------------------------- ----------------------------- ------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------------------- -------- ----------------------- --------------------------------------------
  Linde et al. \[[@B14]\]    Migraine patients             NR                              Acupuncture                                                     ①②③                                                                 At least one clinical outcome related to headache                                       RCT      26 (1151)               Risk of bias approach for Cochrane reviews
  Linde et al. \[[@B7]\]     Episodic migraine patients    Preventive treatment            Acupuncture with or without manual or electrical stimulation    ①②③                                                                 Headache frequency, response, and quality of life                                       RCT      22 (4985)               *α*
  Chen et al. \[[@B15]\]     Migraine patients             NR                              Acupuncture                                                     ③                                                                   Ⓑ                                                                                       RCT      18 (1730)               *β*
  Chen \[[@B16]\]            Migraine patients             NR                              Acupuncture                                                     Acupuncture not according to *meridians*;①②③ and other treatments   Ⓑ                                                                                       RCT      18 (1672)               *α*
  Chu et al. \[[@B17]\]      Migraine patients             NR                              Acupuncture                                                     ②③                                                                  NR                                                                                      RCT      24 (2397)               *α*
  Cui et al. \[[@B18]\]      Migraine patients             NR                              Acupuncture with or without electrical stimulation              ②③ and other treatments.                                            Ⓐ                                                                                       RCT      15 (1288)               *α*
  Dai and Lin \[[@B19]\]     Migraine patients             NR                              Acupuncture                                                     NR                                                                  NR                                                                                      RCT      2 (140)                 *β*
  Gao et al. \[[@B20]\]      NR                            NR                              Acupuncture                                                     ②                                                                   Ⓑ                                                                                       RCT      12 (1744)               *β*
  Yang et al. \[[@B21]\]     Migraine patients             NR                              Acupuncture                                                     ②                                                                   At least one clinical outcome related to headache                                       RCT      10 (997)                *α*
  Zheng and Hai \[[@B22]\]   Migraine patients             NR                              Acupuncture                                                     NR                                                                  NR                                                                                      RCT      33 (3593)               *α*
  Zhao \[[@B23]\]            Menstrual migraine patients   NR                              Acupuncture with or without other treatments                    ②③ and other treatments.                                            ⒶⒷⒸ, pain index, pain time, symptom score, and biochemical indexes.                     RCT      18 (1268)               *α*
  Pu \[[@B24]\]              Migraine patients             Preventive treatment            Acupuncture                                                     ③                                                                   ⒶⒷⒸ, migraine days, migraine frequency, times of analgesics used, and follow-up rate.   RCT      7 (1285)                *α*
  Pu et al. \[[@B25]\]       Migraine patients             Acute treatment                 Acupuncture                                                     ②                                                                   Ⓐ                                                                                       RCT      5 (618)                 *α*
  Song et al. \[[@B26]\]     Migraine patients             Preventive treatment            Acupuncture with or without electrical stimulation or placebo   ③ with or without placebo                                           Ⓑ, pain days, and other outcome.                                                        RCT      18 (1470)               *α*
  Yang et al. \[[@B27]\]     Migraine patients             NR                              Acupuncture                                                     ③                                                                   ⒷⒸ; pain index                                                                          RCT      10 (893)                *α*

^*∗*^NR: not reported in inclusion criteria; ①: no acupuncture; ②: sham acupuncture; ③: drug treatment; Ⓐ: visual analogue scale (VAS) pain score; Ⓑ: efficacy: Ⓒ: adverse events; *α*: Cochrane risk of bias assessment tool \[[@B28]\]; *β*: Jadad scale \[[@B29]\].

###### 

Certainty of evidences reviewed by *GRADE*.

  Study ID                                                                                                                                                           Intervention                  Control                                                                                                                                                                                                                                                                                                                               Outcomes                                                                                                                                                                                              Certainty of evidences
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------
  Linde et al. \[[@B7]\]                                                                                                                                             Acupuncture                   No treatment/usual care                                                                                                                                                                                                                                                                                                               Headache frequency (after treatment) assessed with days per month; response (after treatment and follow-up) assessed with proportion of participants with at least 50% headache frequency reduction   Moderate
  Headache frequency (follow-up) assessed with days per month                                                                                                        Low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Acupuncture                                                                                                                                                        Sham acupuncture              Headache frequency (after treatment and follow-up) assessed with days per month; response (after treatment and follow-up) assessed with proportion of participants with at least 50% headache frequency reduction                                                                                                                     Moderate                                                                                                                                                                                              
  Number of participants dropping out because of adverse effects                                                                                                     Low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Number of participants reporting adverse effects                                                                                                                   High                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Acupuncture                                                                                                                                                        Prophylactic drug treatment   Headache frequency (after treatment and follow-up) assessed with days per month; response (after treatment and follow-up) assessed with proportion of participants with at least 50% headache frequency reduction; number of participants dropping out because of adverse effects; number of participants reporting adverse effects   Moderate                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Chen \[[@B16]\]                                                                                                                                                    Acupuncture                   Drug treatment                                                                                                                                                                                                                                                                                                                        Effective rate                                                                                                                                                                                        Low∼moderate
  Headache frequency, headache intensity, length of headache, combined symptoms, and symptom score                                                                   Moderate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Acupuncture                                                                                                                                                        Other TCM treatment           Effective rate, headache frequency, and combined symptoms                                                                                                                                                                                                                                                                             Low                                                                                                                                                                                                   
  Headache intensity and length of headache                                                                                                                          Very low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Acupuncture                                                                                                                                                        NR                            VAS score and adverse events                                                                                                                                                                                                                                                                                                          Moderate                                                                                                                                                                                              
  TCD-MCA;TCD-ACA; TCD-PCA;TCD-VA                                                                                                                                    Low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  TCD-BA                                                                                                                                                             Very low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Zhao \[[@B23]\]                                                                                                                                                    Acupuncture                   Drug treatment                                                                                                                                                                                                                                                                                                                        Effective rate, pain index, headache intensity, length of headache, combined symptoms score, and symptom score                                                                                        Very low
  Acupuncture with acupuncture on ear                                                                                                                                Drug treatment                Effective rate of mild patients                                                                                                                                                                                                                                                                                                       Low                                                                                                                                                                                                   
  Effective rate, effective rate of moderate patients, effective rate of severe patients, headache score, *β*-EP, Vasopressin, NO, PGF, ET-1, and adverse effects.   Very low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Acupuncture with TCM drug treatment                                                                                                                                Drug treatment                Effective rate                                                                                                                                                                                                                                                                                                                        Very low                                                                                                                                                                                              
  Acupuncture with electrical stimulation                                                                                                                            Drug treatment                Effective rate                                                                                                                                                                                                                                                                                                                        Very low                                                                                                                                                                                              
  Acupuncture for bloodletting                                                                                                                                       TCM drug treatment            Effective rate, headache intensity, and length of headache                                                                                                                                                                                                                                                                            Very low                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Pu \[[@B24]\]                                                                                                                                                      Acupuncture                   Drug treatment                                                                                                                                                                                                                                                                                                                        Migraine days (5-6 months); migraine times (3-4 months); effective rate (5-6 months)                                                                                                                  Moderate
  Migraine days (3-4 months), migraine times (5-6 months), headache intensity (5-6 months), and number of use of analgesics (5-6 months)                             Low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Headache intensity (3-4 months), number of use of analgesics (3-4 months), effective rate (3-4 months), adverse effects, and follow-up rate                        Very low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

^*∗*^TCD: transcranial doppler; MCA: middle cerebral artery; ACA: anterior cerebral artery; posterior cerebral artery: VA: vertebral artery; BA: basilar artery; *β*-EP: beta-endorphin; NO: nitric oxide; PG: prostaglandin; ET: endothelin.

###### 

AMSTAR-2 assessment table.

  AMSTAR-2 items   Yes   Partially yes   No               
  ---------------- ----- --------------- ---- ------ ---- -------
  A01              12    80.0            0    0.0    3    20.0
  A02              0     0.0             0    0.0    15   100.0
  A03              15    100.0           0    0.0    0    0.0
  A04              0     0.0             14   93.3   1    6.7
  A05              12    80.0            0    0.0    3    20.0
  A06              12    80.0            0    0.0    3    20.0
  A07              2     13.3            1    6.7    12   80.0
  A08              4     26.7            8    53.3   3    20.0
  A09              12    80.0            3    20.0   0    0.0
  A10              0     0.0             0    0.0    15   100.0
  A11              15    100.0           0    0.0    0    0.0
  A12              9     60.0            0    0.0    6    40.0
  A13              10    66.7            0    0.0    5    33.3
  A14              9     60.0            0    0.0    6    40.0
  A15              9     60.0            0    0.0    6    40.0
  A16              1     6.7             0    0.0    14   93.3

^*∗*^A01: did the research questions and inclusion criteria for the review include the components of PICO? A02: did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? A03: did the review authors explain their selection of the study designs for inclusion in the review? A04: did the review authors use a comprehensive literature search strategy? A05: did the review authors perform study selection in duplicate? A06: did the review authors perform data extraction in duplicate? A07: did the review authors provide a list of excluded studies and justify the exclusions? A08: did the review authors describe the included studies in adequate detail? A09: did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? A10: did the review authors report on the sources of funding for the studies included in the review? A11: if meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results? A12: if meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? A13: did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? A14: did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? A15: if they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? A16: did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

###### 

MAs outcomes about VAS score.

  Study ID                Outcome           Acute or preventive treatment   Intervention                                         Control   Follow-up time        RCTs (*n*)         I2         Model   MD      95% CI            *P* value
  ----------------------- ----------------- ------------------------------- ---------------------------------------------------- --------- --------------------- ------------------ ---------- ------- ------- ----------------- -----------
  Cui et al. \[[@B18]\]   VAS score         ND                              Acupuncture with or without electrical stimulation   ① or ②    Immediate-term (ND)   5 (667)            87%        REM     −0.32   \[−1.04, 0.41\]   \<0.0001
  Acupuncture             Short-term (ND)   7 (447)                         66%                                                  REM       −1.24                 \[−1.84, −0.64\]   \<0.0001                                     
  Long-term (ND)          5 (318)           95%                             REM                                                  −1.77     \[−2.76, −0.78\]      0.0005                                                          
                                                                                                                                                                                                                                 
  Pu et al. \[[@B25]\]    VAS score         Acute treatment                 Acupuncture                                          ①         2 h                   4 (699)            67%        REM     −0.38   \[−0.83, 0.07\]   0.10
  4 h                     4 (699)           70%                             REM                                                  −0.42     \[−0.96, 0.12\]       0.12                                                            
  VAS score reduction     2 h               3 (579)                         0%                                                   FEM       0.36                  \[0.08, 0.65\]     0.01                                         
  4 h                     3 (579)           0%                              FEM                                                  0.49      \[0.14, 0.84\]        0.01                                                            

^*∗*^ND: not defined; ①: sham acupuncture; ②: drug treatment.

###### 

MAs outcomes about headache situation.

  Study ID                         Outcome                          Acute or preventive treatment   Intervention                          Control                        Follow-up time                   RCTs (*n*)         I2                 Model             Scale   Effect             95% CI             *P* value
  -------------------------------- -------------------------------- ------------------------------- ------------------------------------- ------------------------------ -------------------------------- ------------------ ------------------ ----------------- ------- ------------------ ------------------ -----------
  Linde et al. \[[@B14]\]          Headache frequency               NR                              Acupuncture                           ①                              3-4 months after randomization   4 (2087)           44%                REM               SMD     −0.43              \[−0.60, −0.27\]   \<0.00001
  Headache days                    3-months after randomization     3 (2064)                        12%                                   REM                            MD                               −2.09              \[−2.60, −1.58\]   \<0.00001                                                       
  Analgesic use                    2 months after randomization     2 (218)                         0%                                    REM                            SMD                              −0.29              \[−0.59, 0.01\]    0.057                                                           
  3-4months after randomization    4 (581)                          92%                             REM                                   SMD                            −0.52                            \[−1.22, 0.18\]    0.15                                                                               
  Headache frequency               ②                                2 months after randomization    6 (895)                               57%                            REM                              SMD                −0.23              \[−0.49, 0.04\]   0.09                                          
  3-4months after randomization    8 (1012)                         57%                             REM                                   SMD                            −0.18                            \[−0.44, 0.07\]    0.16                                                                               
  5-6 months after randomization   5 (932)                          55%                             REM                                   SMD                            0.01                             \[−0.25, 0.28\]    0.92                                                                               
  \>6 months after randomization   4 (150)                          0%                              REM                                   SMD                            0.11                             \[−0.22, 0.43\]    0.52                                                                               
  Migraine attacks                 2 months after randomization     4 (327)                         21%                                   REM                            MD                               −0.35              \[−0.74, 0.04\]    0.079                                                           
  3-4 months after randomization   5 (360)                          40%                             REM                                   MD                             −0.11                            \[−0.51, 0.30\]    0.61                                                                               
  5-6 months after randomization   4 (321)                          51%                             REM                                   MD                             0.15                             \[−0.36, 0.65\]    0.57                                                                               
  \>6 months after randomization   4 (150)                          0%                              REM                                   MD                             0.30                             \[−0.10, 0.71\]    0.14                                                                               
  Migraine days                    2 months after randomization     5 (864)                         65%                                   REM                            MD                               −0.80              \[−1.70, 0.11\]    0.084                                                           
  3-4 months after randomization   6 (951)                          52%                             REM                                   MD                             −0.27                            \[−0.98, 0.45\]    0.46                                                                               
  5-6 months after randomization   5 (928)                          37%                             REM                                   MD                             −0.17                            \[−0.82, 0.47\]    0.60                                                                               
  \>6 months after randomization   4 (140)                          0%                              REM                                   MD                             0.35                             \[−0.90, 1.60\]    0.59                                                                               
  Headache days                    2 months after randomization     2 (240)                         43%                                   REM                            MD                               −0.47              \[−2.31, 1.36\]    0.61                                                            
  3-4 months after randomization   2 (238)                          21%                             REM                                   MD                             −0.12                            \[−1.41, 1.17\]    0.86                                                                               
  5-6 months after randomization   2 (233)                          38%                             REM                                   MD                             −0.07                            \[−1.66, 1.52\]    0.93                                                                               
  Analgesic use                    2 months after randomization     5 (368)                         0%                                    REM                            SMD                              −0.08              \[−0.29, 0.14\]    0.50                                                            
  3-4 months after randomization   7 (455)                          74%                             REM                                   SMD                            −0.27                            \[−0.71, 0.16\]    0.21                                                                               
  5-6 months after randomization   6 (410)                          94%                             REM                                   SMD                            −0.56                            \[−1.57, 0.46\]    0.28                                                                               
  \>6 months after randomization   5 (171)                          0%                              REM                                   SMD                            0.02                             \[−0.30, 0.35\]    0.89                                                                               
  Headache frequency               Preventive treatment             Acupuncture                     ③                                     2 months after randomization   3 (553)                          0%                 REM                SMD               −0.24   \[−0.40, −0.08\]   0.003              
  3-4 months after randomization   4 (780)                          0%                              REM                                   SMD                            −0.26                            \[−0.41, −0.11\]   0.00008                                                                            
  5-6 months after randomization   3 (714)                          0%                              REM                                   SMD                            −0.20                            \[−0.35, −0.05\]   0.010                                                                              
  Migraine attacks                 2 months after randomization     2 (241)                         0%                                    REM                            MD                               −0.49              \[−0.91, −0.08\]   0.020                                                           
  3-4 months after randomization   3 (316)                          0%                              REM                                   MD                             −0.32                            \[−0.59, −0.04\]   0.025                                                                              
  5-6 months after randomization   2 (237)                          78%                             REM                                   MD                             −0.47                            \[−1.22, 0.28\]    0.22                                                                               
  Migraine days                    2 months after randomization     2 (503)                         0%                                    REM                            MD                               −0.58              \[−1.09, −0.07\]   0.025                                                           
  3-4 months after randomization   2 (553)                          0%                              REM                                   MD                             −0.70                            \[−1.23, −0.17\]   0.0090                                                                             
  5-6 months after randomization   2 (564)                          0%                              REM                                   MD                             −0.66                            \[−1.18, −0.13\]   0.014                                                                              
  Analgesic use                    2 months after randomization     2 (241)                         28%                                   REM                            SMD                              −0.22              \[−0.53, 0.08\]    0.15                                                            
  3-4 months after randomization   2 (239)                          0%                              REM                                   SMD                            −0.08                            \[−0.33, 0.18\]    0.56                                                                               
  5-6 months after randomization   2 (237)                          0%                              REM                                   SMD                            −0.09                            \[−0.35, 0.17\]    0.49                                                                               
                                                                                                                                                                                                                                                                                                                
  Linde et al. \[[@B24]\]          Headache frequency                                                                                     ①                              Median 3 months                  4 (1199)           7%                 FEM               SMD     −0.56              \[−0.65, −0.48\]   \<0.00001
  ②                                Median 3 months                  12 (1646)                       47%                                   FEM                            SMD                              −0.18              \[−0.28, −0.08\]   0.0004                                                          
  Median 12 months                 9 (1534)                         59%                             FEM                                   SMD                            −0.19                            \[−0.30, −0.09\]   0.0003                                                                             
  ③                                Median 3 months                  3 (739)                         0%                                    FEM                            SMD                              −0.25              \[−0.39, −0.10\]   0.001                                                           
  Median 12 months                 3 (744)                          0%                              FEM                                   SMD                            −0.13                            \[−0.28, 0.01\]    0.08                                                                               
                                                                                                                                                                                                                                                                                                                
  Gao et al. \[[@B20]\]            Headache days                    NR                              Acupuncture                           ②                              After treatment                  3 (775)            45%                FEM               MD      0.18               \[−0.38, 0.73\]    0.54
  After follow-up                  3 (839)                          59%                             FEM                                   MD                             −0.17                            \[−0.69, 0.35\]    0.53                                                                               
                                                                                                                                                                                                                                                                                                                
  Pu \[[@B24]\]                    Migraine days                    Preventive treatment            Acupuncture                           ③                              3-4 months after randomization   4 (755)            3%                 FEM               SMD     −0.30              \[−0.45, −0.16\]   \<0.0001
  5-6 months after randomization   2 (564)                          0%                              FEM                                   SMD                            −0.66                            \[−1.18, −0.13\]   0.01                                                                               
  Migraine frequency               3-4 months after randomization   3 (316)                         0%                                    FEM                            MD                               −0.32              \[−0.59, −0.04\]   0.03                                                            
  5-6 months after randomization   2 (237)                          78%                             REM                                   MD                             −0.47                            \[−1.22, 0.28\]    0.22                                                                               
  Analgesic use                    3-4 months after randomization   4 (388)                         83%                                   REM                            SMD                              −0.34              \[−0.85, 0.17\]    0.20                                                            
  5-6 months after randomization   3 (321)                          0%                              FEM                                   SMD                            −0.22                            \[−0.44, 0.00\]    0.06                                                                               
                                                                                                                                                                                                                                                                                                                
  Song et al. \[[@B26]\]           Headache times                   Preventive treatment            Acupuncture with or without placebo   ③ with or without placebo      Long-term (ND)                   2 (164)            42%                FEM               MD      −0.79              \[−1.39, −0.20\]   0.009

^*∗*^NR: not reported; ND: not defined; ①: no acupuncture; ②: sham acupuncture; ③: drug treatment; FEM: fixed effects model; REM: random effects model.

###### 

MAs outcomes about efficacy.

  Study ID                                   Outcome                                                 Acute or preventive treatment   Intervention   Control   Follow-up time                   RCTs (*n*)       I2                Model             Scale       Effect   95% CI            *P* value
  ------------------------------------------ ------------------------------------------------------- ------------------------------- -------------- --------- -------------------------------- ---------------- ----------------- ----------------- ----------- -------- ----------------- -----------
  Linde et al. \[[@B14]\]                    Response (attack frequency reduction of at least 50%)   ND                              Acupuncture    ①         3-4 months after randomization   4 (2376)         0%                REM               RR          2.33     \[2.02, 2.69\]    \<0.00001
  ②                                          2 months after randomization                            7 (1091)                        59%            REM       RR                               1.38             \[0.96, 1.97\]    0.08                                                     
  3-4 months after randomization             11 (1225)                                               14%                             REM            RR        1.13                             \[0.95, 1.35\]   0.16                                                                       
  5-6 months after randomization             6 (1054)                                                64%                             REM            RR        1.19                             \[0.86, 1.63\]   0.29                                                                       
  \>6 months after randomization             3 (132)                                                 10%                             REM            RR        1.01                             \[0.51, 1.99\]   0.98                                                                       
  ③                                          2 months after randomization                            2 (566)                         0%             REM       RR                               1.35             \[1.09, 1.67\]    0.006                                                    
  3-4 months after randomization             2 (566)                                                 0%                              REM            RR        1.20                             \[0.98, 1.46\]   0.08                                                                       
  5-6 months after randomization             2 (564)                                                 62%                             REM            RR        1.35                             \[0.89, 2.05\]   0.16                                                                       
                                                                                                                                                                                                                                                                                           
  Linde et al. \[[@B7]\]                     Response (at least 50% frequency reduction)             Preventive treatment            Acupuncture    ①         Median 3 months                  4 (2519)         7%                FEM               RR          2.40     \[2.08, 2.76\]    \<0.00001
  ②                                          Median 3 months                                         14 (1825)                       48%            FEM       RR                               1.23             \[1.11, 1.36\]    \<0.00001                                                
  Median 12 months                           11 (1683)                                               61%                             FEM            RR        1.25                             \[1.13, 1.39\]   \<0.00001                                                                  
  ③                                          Median 3 months                                         3 (743)                         0%             FEM       RR                               1.24             \[1.08, 1.44\]    0.003                                                    
  Median 12 months                           3 (744)                                                 0%                              FEM            RR        1.11                             \[0.97, 1.26\]   0.12                                                                       
                                                                                                                                                                                                                                                                                           
  Chen et al. \[[@B15]\]                     Effective rate (headache relieved or disappeared)       NR                              Acupuncture    ③         ND                               18 (1730)        0%                FEM               OR          5.11     \[3.81, 6.85\]    \<0.00001
                                                                                                                                                                                                                                                                                           
  Chen \[[@B16]\]                            Effective rate (headache controlled or disappeared)     NR                              Acupuncture    ③         ND                               18 (1606)        42%               FEM               RR          1.21     \[1.16, 1.27\]    \<0.00001
                                                                                                                                                                                                                                                                                           
  Chu et al. \[[@B17]\]                      Effective rate (ND)                                     NR                              Acupuncture    ②         ND                               2 (139)          0%                FEM               OR          5.70     \[1.88, 17.27\]   0.002
  ③                                          ND                                                      20 (2096)                       13%            FEM       OR                               3.96             \[3.02, 5.19\]    \<0.00001                                                
  TCM drug treatment                         ND                                                      2 (162)                         0%             FEM       OR                               7.58             \[2.30, 24.92\]   0.0009                                                   
                                                                                                                                                                                                                                                                                           
  Dai and Lin \[[@B19]\]                     Cure rate (ND)                                          NR                              Acupuncture    ③         ND                               2 (140)          0%                FEM               OR          3.02     \[1.00, 9.07\]    0.05
  Response rate (include cure rate)          NR                                                      ND                              2 (140)        0%        FEM                              OR               5.37              \[2.57, 11.21\]   \<0.00001                              
  Effective rate (cure and response rates)   NR                                                      ND                              2 (140)        0%        FEM                              OR               4.85              \[1.69, 13.94\]   0.003                                  
  Gao et al. \[[@B20]\]                      Effective rate (at least 50% frequency reduction)       NR                              Acupuncture    ②         ND                               8 (1253)         0%                FEM               OR          1.28     \[1.02, 1.61\]    0.03
                                                                                                                                                                                                                                                                                           
  Zheng and Hai \[[@B22]\]                   Effective rate (ND)                                     NR                              Acupuncture    ②         ND                               3 (217)          69%               REM               RR          1.87     \[1.17, 2.98\]    0.009
  ③                                          ND                                                      28 (3059)                       81%            REM       RR                               1.24             \[1.16, 1.33\]    \<0.00001                                                
  TCM drug treatment                         ND                                                      3 (225)                         0%             FEM       RR                               1.29             \[1.14, 1.45\]    \<0.00001                                                
                                                                                                                                                                                                                                                                                           
  Zhao \[[@B23]\]                            Effective rate (ND)                                     NR                              Acupuncture    ③         ND                               8 (686)          50%               REM               RR          1.19     \[1.07, 1.32\]    0.0010
  Acupuncture with acupuncture on ear        ③                                                       3 months                        2 (152)        0%        FEM                              RR               1.18              \[1.05, 1.33\]    0.005                                  
  Acupuncture with TCM drug treatment        ③                                                       At least 6 months               3 (257)        98%       REM                              RR               1.24              \[0.61, 2.52\]    0.0009                                 
                                                                                                                                                                                                                                                                                           
  Pu \[[@B24]\]                              Effective rate (at least 50% frequency reduction)       Preventive treatment            Acupuncture    ③         3-4 months after randomization   4 (772)          57%               REM               RR          1.41     \[1.06, 1.88\]    0.02
  5-6 months after randomization             2 (564)                                                 0%                              FEM            RR        1.18                             \[0.97, 1.43\]   0.11                                                                       
                                                                                                                                                                                                                                                                                           
  Song et al. \[[@B26]\]                     Effective rate (ND)                                     Preventive treatment            Acupuncture    ③         1-3 months                       15 (1218)        35%               FEM               OR          2.76     \[2.03, 3.77\]    \<0.00001
  \>3 months                                 7 (642)                                                 0%                              FEM            OR        4.17                             \[2.80, 6.20\]   \<0.00001                                                                  
                                                                                                                                                                                                                                                                                           
  Yang et al. \[[@B27]\]                     Efficacy                                                NR                              Acupuncture    ③         Short-term (ND)                  9 (821)          69%               REM               RR          1.27     \[1.11, 1.45\]    0.0004
  Long-term (ND)                             4 (232)                                                 87%                             REM            RR        1.76                             \[1.05, 2.94\]   0.03                                                                       

^*∗*^NR: not reported; ND: not defined; ①: no acupuncture; ②: sham acupuncture; ③: drug treatment; FEM: fixed effects model; REM: random effects model.

###### 

MAs outcomes about adverse events.

  Study ID                                                     Outcome                                                      Acute or preventive treatment   Intervention   Control   Follow-up time   RCTs (*n*)       I2               Model            Scale   Effect   95% CI            *P* value
  ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------- -------------- --------- ---------------- ---------------- ---------------- ---------------- ------- -------- ----------------- -----------
  Linde et al. \[[@B14]\]                                      Number of patients reporting adverse effects                 ND                              Acupuncture    ②         NR               4 (838)          73%              FEM              OR      0.47     \[0.34, 0.65\]    \<0.00001
  Number of patients dropping out due to adverse effects       NR                                                           2 (191)                         0%             FEM       OR               0.10             \[0.01, 0.78\]   0.028                                               
                                                                                                                                                                                                                                                                                            
  Linde et al. \[[@B7]\]                                       Number of participants dropping out due to adverse effects   Preventive treatment            Acupuncture    ①         NR               7 (931)          0%               FEM              OR      2.84     \[0.43, 18.71\]   0.28
  Number of participants reporting adverse effects             4 (1414)                                                     0%                              FEM            OR        1.15             \[0.85, 1.56\]   0.35                                                                 
  Number of participants with serious adverse events           6 (1071)                                                     0%                              FEM            OR        1.29             \[0.43, 3.83\]   0.65                                                                 
  Number of participants dropping out due to adverse effects   ②                                                            NR                              4 (451)        0%        REM              OR               0.27             \[0.08, 0.86\]   0.027                              
  Number of participants reporting adverse effects             5 (931)                                                      78%                             REM            OR        0.25             \[0.10, 0.62\]   0.0027                                                               
  Number of participants with serious adverse events           3 (721)                                                      0%                              REM            OR        1.33             \[0.38, 4.73\]   0.66                                                                 
                                                                                                                                                                                                                                                                                            
  Chen \[[@B16]\]                                              Number of adverse effects                                    ND                              Acupuncture    ND        NR               5 (567)          0%               FEM              RR      0.11     \[0.03, 0.49\]    0.003
                                                                                                                                                                                                                                                                                            
  Pu \[[@B24]\]                                                Rate of adverse events                                       Preventive treatment            Acupuncture    ②         NR               7 (1126)         77%              REM              RR      0.33     \[0.17, 0.64\]    0.001

^*∗*^NR: not reported; ND: not defined; ①: sham acupuncture; ②: drug treatment; FEM: fixed effects model; REM: random effects model.

[^1]: Guest Editor: Fang Zeng
